191 related articles for article (PubMed ID: 38227591)
21. High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.
Lin YF; Tseng IJ; Kuo CJ; Lin HY; Chiu IJ; Chiu HW
J Cell Mol Med; 2018 Apr; 22(4):2458-2468. PubMed ID: 29392887
[TBL] [Abstract][Full Text] [Related]
22. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
23. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
[TBL] [Abstract][Full Text] [Related]
24. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
26. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
27. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
29. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
Yi M; Peng C; Xia B; Gan L
Clin Breast Cancer; 2022 Feb; 22(2):e191-e198. PubMed ID: 34284965
[TBL] [Abstract][Full Text] [Related]
30. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
32. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
34. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
35. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
36. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
Chen J; Zhu M; Zou L; Xia J; Huang J; Deng Q; Xu R
Acta Biochim Biophys Sin (Shanghai); 2020 Aug; 52(8):801-809. PubMed ID: 32632453
[TBL] [Abstract][Full Text] [Related]
38. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq.
Xu J; Qin S; Yi Y; Gao H; Liu X; Ma F; Guan M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077333
[TBL] [Abstract][Full Text] [Related]
39. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
40. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
